Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 585-591, November 2009

Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer

  • Teruo Inamoto, M.D.

      Affiliations

    • Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Jay B. Shah, M.D.

      Affiliations

    • Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Ashish M. Kamat, M.D.

      Affiliations

    • Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-713-792-3250; fax: +1-713-794-4824

Received 14 August 2008; received in revised form 4 November 2008; accepted 9 November 2008. published online 23 January 2009.

Abstract 

The peroxisome proliferator-activated receptor (PPAR) family is an important group of transcription factors that regulates immune surveillance, cell proliferation, fatty acid regulation, and angiogenesis—functions which have all been implicated in the pathogenesis of bladder cancer. One particular subtype, PPARγ, is expressed at higher levels in bladder cancer specimens than in benign urothelium, and is an attractive molecular target for the development of novel treatment strategies for bladder cancer. In this review, we summarize the data available regarding relevance of PPARγ in bladder cancer and discuss the potential value of PPAR-targeted treatment of bladder cancer.

Keywords: Peroxisome proliferator-activated receptor, PPARγ, Bladder cancer, Carcinogenesis, Rosiglitazone

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1078-1439(08)00327-X

doi:10.1016/j.urolonc.2008.11.002

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 585-591, November 2009

Article Tools